

Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers

Carolina Perales-Chorda^{1*} | David Obeso^{2,3*}  | Laura Twomey^{2,3} |
 Ayelén Rojas-Benedicto⁴ | Leonor Puchades-Carrasco⁴ | Marta Roca⁵ |
 Antonio Pineda-Lucena^{4,6} | José Julio Laguna^{7,8}  | Coral Barbas³ | Vanesa Esteban^{8,9} |
 Jaume Martí-Garrido¹ | Ethel Ibañez-Echevarria¹ | Ramón López-Salgueiro¹ |
 Domingo Barber²  | Alma Villaseñor^{2*}  | Dolores Hernández Fernández de Rojas^{1*}

¹Allergy Department of Hospital, Universitari i Politècnic La Fe, Valencia, Spain

²IMMA, Instituto de Medicina Molecular Aplicada, Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe| Boadilla del Monte, Madrid, 28660, Spain

³CEMBIO, Centre for Metabolomics and Bioanalysis, Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe| Boadilla del Monte, Madrid, 28660, Spain

⁴Drug Discovery Unit, Health Research Institute La Fe, Valencia, Spain

⁵Analytical Unit, Health Research Institute Hospital La Fe, Valencia, Spain

⁶Molecular Therapeutics Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain

⁷Allergy Unit, Allergo-Anaesthesia Unit, Hospital Central de la Cruz Roja, Madrid, Spain

⁸Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, Madrid, Spain

⁹Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain

Correspondence

Dolores Hernández Fernández de Rojas, MD, PhD, Allergy Research Group - IIS - Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, 106, 46026 València, Valencia, España. Email: hernandez_dol@gva.es

Alma Villaseñor, PhD, Department of Basic Medical Sciences, Faculty of Medicine. San Pablo CEU University, Campus Montepríncipe. Crtra. Boadilla del Monte km 5.3., CP 28668 Boadilla del Monte. Madrid, Spain. Email: alma.villaseñor@ceu.es

Funding information

This work was supported by Foundation for Research of the Spanish Society of Allergy and Clinical Immunology (SEALC) (Aid 2014), ISCIII (Project numbers, PI19/00044, PI15/02256, PI19/01273 and PI18/00348) cofounded by FEDER

Abstract

Background: Despite the increasing incidence of anaphylaxis, its underlying molecular mechanisms and biomarkers for appropriate diagnosis remain undetermined. The rapid onset and potentially fatal outcome in the absence of managed treatment prevent its study. Up today, there are still no known biomarkers that allow an unequivocal diagnosis. Therefore, the aim of this study was to explore metabolic changes in patients suffering anaphylactic reactions depending on the trigger (food and/or drug) and severity (moderate and severe) in a real-life set-up.

Methods: Eighteen episodes of anaphylaxis, one per patient, were analysed. Sera were collected during the acute phase (T1), the recovery phase (T2) and around 2–3 months after the anaphylactic reaction (T0: basal state). Reactions were classified following an exhaustive allergological evaluation for severity and trigger. Sera samples were analysed using untargeted metabolomics combining liquid chromatography coupled to mass spectrometry (LC-MS) and proton nuclear magnetic resonance spectroscopy (¹H-NMR).

*These authors have equally contributed.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Clinical & Experimental Allergy* published by John Wiley & Sons Ltd.

for the thematic network and co-operative research centres ARADyAL RD16/0006/0013, RD16/0006/0015, RD16/0006/0030, RD16/0006/0033. This work was also supported by the grant from Ministerio de Ciencia, Innovación y Universidades RTI2018-095166-B-I00. This work was supported by the Generalitat Valenciana and European Regional Development Fund (FEDER) funds (PO FEDER of Comunitat Valenciana 2014-2020), and the grant from Alfonso X El Sabio University foundation. A.V. is funded by a postdoctoral research fellowship from ARADyAL

Results: 'Food T1 vs T2' and 'moderate T1 vs T2' anaphylaxis comparisons showed clear metabolic patterns during the onset of an anaphylactic reaction, which differed from those induced by drugs, food + drug or severe anaphylaxis. Moreover, the model of food anaphylaxis was able to distinguish the well-characterized IgE (antibiotics) from non-IgE-mediated anaphylaxis (nonsteroidal anti-inflammatory drugs), suggesting a differential metabolic pathway associated with the mechanism of action. Metabolic differences between 'moderate vs severe' at the acute phase T1 and at basal state T0 were studied. Among the altered metabolites, glucose, lipids, cortisol, betaine and oleamide were observed altered.

Conclusions: The results of this exploratory study provide the first evidence that different anaphylactic triggers or severity induce differential metabolic changes along time or at specific time-point, respectively. Besides, the basal status T0 might identify high-risk patients, thus opening new ways to understand, diagnose and treat anaphylaxis.

KEYWORDS

¹H-NMR, drug anaphylaxis, food anaphylaxis, grading anaphylaxis, IgE-mediated anaphylaxis, untargeted metabolomics, UPLC-MS

1 | INTRODUCTION

Anaphylaxis is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death.¹ Its incidence is estimated to be between 50 and 103 cases per 100,000 person-years. Though the mortality rate has remained stable, there has been an increase in the number of hospital admissions due to anaphylaxis of up to 7 times in the last 10 years.² From a clinical point of view, it is a complex syndrome that can involve multiple organs, including the skin and those of the digestive, respiratory, nervous and cardiovascular systems.³

Although potentially any substance can cause an anaphylactic reaction, the most common aetiological agents in adults are drugs, foods and hymenoptera stings. The allergen triggers the release of chemical mediators by the effector cells (mainly mast cells and basophils), which cause the symptoms.^{4,5} The nature of the allergen determines the molecular mechanism by which mediators are released: dependent or independent of immunoglobulin E (IgE). IgE-dependent anaphylaxis has been clearly characterized in humans⁶ in food-induced anaphylaxis. In contrast, IgE-independent mechanisms (including those mediated by IgG, by the complement system, and direct activation of mast cells and basophils by drugs) have been studied in experimental animal models⁷⁻¹⁰ and barely in humans.^{11,12}


The diagnosis is carried out at the time of the reaction and is always based on clinical symptoms. Therefore, it often depends on the qualifications and experience of the specialist that assesses the patient since objective biomarkers that fully discriminate an anaphylactic event do not exist. Although, measurement of serum tryptase¹³ and histamine¹⁴ at the time of the reaction may support the diagnosis, the level of these biomarkers is not altered in all cases nor

Key Messages

- Different triggers in humans (Food/Drug) have different metabolic profiles related to their action's mechanism.
- Severity of anaphylactic reaction produces different metabolic changes with a higher number in moderate.
- At basal state, different metabolic changes were found between moderate and severe anaphylactic reactions.

it is correlated with the course of the reaction, the severity and the cause or allergen trigger. Moreover, diagnosis by both biomarkers presents sensitivity and specificity limitations¹⁵. Thus, their usefulness is currently questioned.¹⁶ The treatment of anaphylaxis targets only symptom control as no specific treatment exists. Injectable epinephrine is universally agreed as the first-line therapy.¹⁷⁻¹⁹

Metabolomics is the science used to characterize the metabolic response in a pathology.²⁰ Because of this, it is a promising tool in the study of anaphylactic reactions. The metabolome is closely linked to the phenotype and provides an extremely useful tool in the characterization of the disease. Although there is no single technique that detects the entire metabolome, the combination of mass spectrometry (MS) and proton nuclear magnetic resonance spectroscopy (¹H-NMR) provides complementary information that allows to identify a wider range of metabolites per sample.²¹ Compared to other omics, such as transcriptomics or genomics, suitable validation of metabolites found after exploratory studies is carried out through the development of analytical methodologies. This process is usually laborious depending on the number of metabolites and their



GRAPHICAL ABSTRACT

For the first time, the metabolic profile of anaphylaxis in a real-life set-up was characterized and provide evidence that different triggers (Food and Drug) and severity (Moderate and Severe) induce differential metabolic changes improving clinical practice. Eighteen episodes of anaphylaxis with a full clinical characterization were analyzed by metabolomics. The time points were: acute phase (T1), recovery phase (T2) and basal state (T0). Basal status might identify high risk patients, thus opening new ways to understand, diagnose and treat anaphylaxis

physicochemical properties and is conditioned by the availability of commercial standards. Furthermore, this validation should be performed in bigger cohorts. Studies using metabolomic fingerprinting with a reduced number of samples have succeed in other allergic phenotypes such as asthma and food allergy.^{20,22-24}

Anaphylaxis is a field yet to be explored since there are still no biomarkers that allow a sensitive and specific molecular diagnosis nor the severity of the reaction.²⁵ There are no indicators that predict the risk of certain patients suffering a severe allergic reaction. In many cases, the pathway by which the reaction takes place, dependent or independent of IgE, is also uncertain. Despite its great potential, metabolomics has been applied very slightly in human anaphylaxis. The unpredictable occurrence and outcome promote relevant technical and ethical difficulties. Moreover, controlled provocation set-ups do not reflect severe life-threatening reactions since on behalf of patient safety challenges are stopped.²⁶⁻²⁸

The aim of this exploratory study was to characterize the metabolic changes in patients suffering from anaphylaxis triggered either by foods or drugs in a real-life set-up comparing their acute phase (T1) versus their recovery phase (T2). Complementary, metabolite differences between moderate and severe anaphylactic reactions during the acute phase (T1) and basal state (T0) months later of anaphylactic reaction were obtained.

2 | MATERIALS AND METHODS

2.1 | Patient recruitment

A prospective clinical and observational study of patients with anaphylactic reactions was performed. Patients of all ages and both sexes were recruited at outpatient clinics and the departments of

Emergency and other services at Hospital La Fe. All fulfilled clinical criteria of anaphylaxis, and severity was graded following the classification by Brown, et al.²⁹ Patients were classified as food, drug or idiopathic origin, as well as in mild, moderate or severe according to the number of organs affected and clinical symptoms. The allergy evaluation was conducted by the Allergology Service of Hospital La Fe. The ethical committee approved the study protocol, and all subjects were informed and provided written consent.

2.2 | Experimental design

Serum samples were taken during the acute moment of the reaction at the first moment of medical attention (<2 h, hereafter referred as 'T1') and after clinical recovery (approximately 2-4 h later, referred to as 'T2'). Patients were treated according to the Galaxy 2016 practical guide, using all necessary drugs to rescue them. Subsequently, between 2 and 3 months after the anaphylaxis, a sample was taken when the allergy evaluation was performed (basal state, called 'T0'). For sample collection at T0, patients were asked to have a fasting time of 8 h and to avoid regular medication. Medication received before sample collection at T1, T2 and T0 have been included in a table (see Table S1). A scheme of the experimental design is shown in Figure 1.

2.3 | Sample Collection and clinical parameters

Samples were collected in a vacutainer tube (Ref. 368965) and processed immediately after blood extraction following specific standard operating procedures.³⁰⁻³² Full details are described at Supporting Information (SI-Part 1). Sample aliquots were stored at -80°C until further analyses.

2.4 | Tryptase determination

Serum tryptase was measured following the manufacturer's instructions using the UniCAP-Tryptase fluoro-enzyme-immunoassay (FEIA) (Thermo Fisher Scientific, Uppsala, Sweden). Tryptase elevation was considered when a 20% (± 2 ng/ml) of increment from baseline was observed.

2.5 | Metabolomic analyses

Samples were measured using a multiplatform analysis: ultra-performance liquid chromatography coupled to mass spectrometry (UPLC-MS, Agilent 6550) and proton nuclear magnetic resonance spectroscopy (¹H-NMR, Bruker 500MHz). UPLC-MS and ¹H-NMR analyses were carried out in the Analytical Unit and in the Drug Discovery Unit, respectively, both at the Health Research Institute La Fe. Full descriptions following previous publications are available in SI-Part2³⁰⁻³². Regarding UPLC-MS, a tentative identification was performed using an online software called CEU Mass Mediator tool.^{33,34} Tandem mass spectrometry was used to confirm the annotation. Data were uploaded to Metabolomics Workbench webpage (ST001655 and ST001656).

3 | RESULTS

3.1 | Patient characteristics and clinical outcome

A total of 18 anaphylactic episodes occurring in 12 women (67%) and 6 men (33%) with a mean age of 42 years old (± 20.1 SD) were analysed (Table 1). After the allergological evaluation, the episodes of anaphylaxis were classified according to the identified (or suspected) trigger. The resulting groups were 9 drug allergy (50%), 6 food allergy




FIGURE 1 Experimental design. T, time-point

TABLE 1 Clinical, allergy and therapeutic characteristics of patients with anaphylactic reactions

Anaphylaxis trigger	Demographics			Systems involved				Tryptase levels			Allergy study						
	Code	Age (y)	Gender	Skin	Brea.	Diges.	Neur.	CV	Sev	Time	Value	Incr.	Diagnostic allergy ^{&}	SPT	BAT	sigE	STC
FOOD	P2	10	W	YES	YES	NO	NO	NO	MOD	T0	1.7	YES	Walnut	POS	ND	POS	ND
										T1	3.8						
										T2	2.5						
FOOD	P8	31	W	YES	YES	NO	NO	NO	MOD	T0	3.5	NO	Mussel	POS	ND	POS	ND
										T1	5.4						
										T2	4.9						
FOOD	P9	27	W	YES	YES	NO	NO	NO	MOD	T1	4.1	NO	Cashew	POS	ND	POS	ND
										T2	4.4						
										T0	5.7	YES					
T1	9.1																
T2	5.1																
FOOD	P15	21	W	YES	YES	NO	NO	NO	MOD	T0	1.8	YES	LTP allergy (salad)	POS	ND	POS	ND
										T1	11.2						
										T2	13.0						
FOOD	P17	16	M	YES	YES	NO	YES	NO	MOD	T0	1.0	YES	LTP allergy (nut)	POS	ND	POS	ND
										T1	8.3						
										T2	9.5						
DRUG	P1	66	M	YES	YES	NO	NO	NO	MOD	T0	8.3	YES	Carmellose	POS	POS	NA	ND
										T1	10.1						
										T2	19.6						
DRUG	P3	33	M	YES	YES	NO	NO	NO	MOD	T0	4.6	NO	lomeprol	NEG	POS	NA	ND
										T1	4.6						
DRUG	P4	68	M	YES	YES	NO	YES	YES	SEV	T0	6.4	YES	Amoxicillin	POS	NEG	POS	ND
										T1	20.3						
										T2	24.0						
DRUG	P7	54	W	YES	YES	YES	YES	NO	SEV	T0	6.3	YES	Moxifloxacin	POS	NEG	NA	ND
										T1	17.8						
										T2	23.5						
DRUG	P12	39	W	YES	NO	NO	YES	YES	SEV	T0	1.5	YES	Metamizole	POS	POS	NA	ND
										T2	14.6						

(Continues)

TABLE 1 (Continued)

Anaphylaxis trigger	Demographics		Systems involved				Tryptase levels			Allergy study							
	Code	Age (y)	Gender	Skin	Brea.	Diges.	Neur.	CV	Sev	Time	Value	Incr.	Diagnostic allergy ^{&}	SPT	BAT	slgE	STC
DRUG	P13	65	W	YES	YES	NO	NO	YES	SEV	T0	5.0	YES	Diclofenac	POS	NEG	NA	POS
										T1	9.2						
										T2	14.0						
DRUG	P14	79	M	YES	YES	NO	NO	NO	MILD	T0	10.2	NO	Ampicillin	POS	ND	POS	ND
										T1	11.4						
DRUG	P16	37	W	YES	NO	NO	NO	NO	MOD	T0	5.0	YES	Clavulanic acid	POS	ND	NA	ND
										T1	86.7						
										T2	76.7						
DRUG	P18	50	W	YES	NO	NO	YES	YES	SEV	T0	5.9	YES	Celebrex	NEG	ND	ND	POS
										T1	14.0						
										T2	9.3						
IDIOPATHIC	P5	60	M	YES	YES	NO	NO	NO	MOD	T1	4.9	NO	Idiopathic	NEG	ND	NEG	NEG
										T2	3.2						
IDIOPATHIC	P6	36	W	YES	YES	NO	ND	YES	SEV	T0	3.0	NO	Idiopathic	NEG	ND	NEG	NEG
										T1	3.8						
										T2	3.1						
IDIOPATHIC	P11	21	W	YES	YES	NO	YES	YES	SEV	T0	4.1	NO	Idiopathic	NEG	NEG	ND	NEG
										T1	4.6						
										T2	4.7						

Abbreviations: BAT, basophil activation test; Brea., breathing; CV, cardiovascular; Diges., Digestive; Incr., increase; M, man; MOD, moderate; MTO, basal time (2–3 months after reaction); NA, not available; ND, not performed; NEG, negative; Neur., neurologic; POS, positive; Sev, reaction severity; SEV, severe; SPT, skin prick test; STC, specific test challenge; T1, acute phase of reaction; T2, recovery phase; W, woman; y, years old.

[&]For diclofenac and metamizole, LTP-mediated anaphylaxis was rejected and the reaction was purely due to the NSAID.

(33%) and 3 idiopathic (17%). Regarding the severity of the anaphylactic reaction, 9 were moderate (50%), 8 severe (44%) and 1 mild (6%). The results showed an elevation of tryptase during anaphylaxis in 66% of patients with food reactions (4 out of 6) and 88% in those with drug reactions (7 out of 8). Interestingly, patients with reactions classified as idiopathic did not show elevation of tryptase during the reaction. These three patients were excluded from the following analyses since their cause of anaphylaxis could mislead the analysis. All patients recovered favourably from the reaction after treatment and were stabilized within a few hours (2–4 h). Intramuscular epinephrine was used as first-choice treatment for the anaphylactic reactions in 8 patients (45%). All patients were treated with antihistamines and corticosteroids (Table S1).

Drug and food triggers were the most common causes of anaphylaxis in this study, and we will focus on these groups (Table 2). Inside the food group, most patients presented moderate reactions except one severe case. In the drug group, five patients had severe reactions, three were moderate and one mild. The groups were balanced in terms of sex, severity or allergen trigger. The age was significantly higher in drug and severe groups compared to food and moderate groups, respectively ($p \leq 0.004$). Furthermore, the number of leucocytes was found to be significantly higher in food anaphylaxis compared to the drug anaphylaxis group ($p = 0.03$). The rest of the clinical parameters did not show significant differences between the groups of study.

3.2 | Metabolic profiling

Metabolomic profile of samples was obtained using LC-MS (positive and negative) and $^1\text{H-NMR}$. Quality of LC-MS data was assessed by the clustering of quality control injections in PCA (Figure S1). Samples were explored following two different approaches: (1) based on the progression of the anaphylaxis reaction: comparing T1 vs T2 in the different anaphylactic conditions (food, drug, food + drug, severe and moderate anaphylaxis), and (2) based on the effect of the severity of the reaction in a particular time-point (severe vs moderate either at T0 or T1).

3.3 | Food anaphylactic reactions present a specific metabolic fingerprint

To test whether the drug- and food-triggered anaphylaxis cases experienced the same metabolic changes between T1 and T2, both groups were compared together ('food + drug T1 vs T2') and separately ('food T1 vs T2' and 'drug T1 vs T2') using multivariate statistics. We observed that only food anaphylaxis models 'T1 vs T2' in LC-MS positive mode showed good quality parameters for PCA and OPLSDA (Figure 2A,B). In particular, the cross-validated OPLSDA model ($R^2 = 1.00$ and a $Q^2 = 0.79$) showed a complete separation of the groups (Figure 2B). On the other hand, no model was obtained for drug or food + drug anaphylaxis, which means no major differences in 'T1 vs T2'.

The 'food anaphylaxis T1 vs T2' model was thought to reflect metabolic changes specifically associated with IgE-mediated anaphylactic reaction. To test this hypothesis, we used the ability of the model to classify the drug anaphylaxis samples. Figure 2C shows the prediction plot for the drug samples ($n = 9$). Interestingly, the prediction model separated the drug anaphylaxis samples into two groups. On one hand, 4 patients, allergic to antibiotics (beta-lactam: ampicillin, amoxicillin and clavulanic acid, and quinolone: moxifloxacin), were perfectly classified based on the time from anaphylactic reaction (T1 or T2) with a prediction score $>75\%$. On the other hand, 5 patients, from which 3 suffered anaphylactic reactions caused by nonsteroidal anti-inflammatory drugs (NSAIDs: celecoxib, metamizole and diclofenac), 1 patient allergic to carmellose, 1 patient allergic to a contrast medium (iomeprol), were not classified in any food anaphylaxis time (T1 or T2; Table S2) with a prediction score $<75\%$.

Focussing now in the 'food anaphylaxis T1 vs T2' in LC-MS positive, 73 significantly altered metabolites were obtained by univariate analysis. These were represented using a heat map with a hierarchical clustering (Figure 2D), and all patients were correctly grouped. Identification analysis allowed to observe an alteration in the levels of phospholipid-related metabolites, including phosphatidylcholines such as PC (16:0/16:1), lysophosphatidylethanolamine (LysoPE(19:0)/LysoPE(P-19:1)) and choline (Figure 2E). Furthermore, based on the results of the $^1\text{H-NMR}$ analysis of 'food T1 vs T2', significantly increased levels of acetate, phenylalanine, lysine, creatine and glutamine were characteristic of samples in T1 (Table S3).

3.4 | Severity of the reaction during time (T1 vs T2)

Once we established the differences regarding the trigger, we analysed the metabolic changes associated with the severity. Therefore, 'T1 vs T2' were compared independently in moderate and severe anaphylaxis reactions.

The most relevant model was obtained for 'moderate T1 vs T2' using the $^1\text{H-NMR}$ data. Separation of groups was observed both in PCA and OPLSDA models (Figure 3A,B). The cross-validated OPLSDA model showed $R^2 = 0.78$, $Q^2 = 0.56$, which correctly classified 93% of the samples from the model (13 out of 14 patients). Moreover, a heat map was built using the $^1\text{H-NMR}$ data that showed statistically significant differences between 'moderate T1 vs T2' ($n = 111$; $p < 0.05$), illustrating a clear metabolic signature (Figure 3C). Moderate reaction group was characterized by the increase in T1 of lactate, acetate, arginine, glutamine, isoleucine, leucine, valine, phenylalanine, proline and creatinine among others (Table S4). The trajectories of these metabolites are represented in Figure 3D. On the other hand, in LC-MS, choline was found increased at T1, while PCs and PEs were decreased.

All these changes were not observed in the 'severe T1 vs T2' comparison. However, the univariate analysis in LC-MS revealed an increase in PC(20:4/20:4) and a PE metabolite at T1 (Table S5).

TABLE 2 Patients and summary of clinical variables included in each comparison: (A) anaphylaxis trigger and (B) severity of the reaction

	(A) Anaphylaxis trigger			(B) Severity			Test
	Food	Drug	p-value	Mild	Moderate	Severe	p-value
N° of subjects (n = 15)	6	9	—	1	8	6	—
Mean age (SD) (years)	26 (14)	55 (16)	0.004**	79 (0) ^c	30 (17)	55 (11)	0.006**
Female sex	5 (83%)	5 (56%)	0.580 ^b	0%	63%	83%	0.245 ^a
Anaphylaxis severity							Chi-square (χ^2)
Mild	0	1	0.156 ^a	—	—	—	—
Moderate	5	3	—	—	—	—	—
Severe	1	5	—	—	—	—	—
Anaphylaxis trigger	—	—	—	—	—	—	Chi-square (χ^2)
Food	—	—	—	0	5	1	0.156 ^a
Drug	—	—	—	1	3	5	—
Measurement at T0							Mann-Whitney U test
N° of samples (n = 11)	4	7	—	1	6	4	—
Total IgE (SD) (kUA/L)	367 (398)	891 (1819)	0.78	—	306 (239)	217 (323)	0.47
Clinical parameters at T1							Mann-Whitney U test
N° of samples (n = 8)	5	3	—	—	5	3	—
Creatinine (SD) (mg/dl)	0.883 (0.121)	0.796 (0.223)	0.571	—	0.828 (0.151)	0.830 (0.275)	1.000
Leucocytes (SD) (/μL)	12826 (2975)	8164 (1778)	0.036*	—	9580 (2064)	10466 (5127)	1.000
Lymphocytes (SD) (/μL)	3116 (1932)	3932 (1167)	0.393	—	3858 (1778)	3240 (632)	0.786
Eosinophils (SD) (/μL)	90 (51)	136 (149)	0.928	—	158 (139)	53 (5)	0.074
Platelets (SD) (/μL)	301666 (42524)	281600 (54173)	0.571	—	293400 (49847)	282000 (54442)	0.785
Prothrombin time (SD) (s)	ND	ND	—	—	14.3 (1.767) ^d	12.9 (1.501)	0.571
Reactive protein (SD) (mg/L)	ND	ND	—	—	2.133 (0.751) ^e	2.067 (1.498)	1.000

Student's t test, Mann-Whitney, chi-square (χ^2) or Fisher's exact test were applied depending on the distribution and type of the data using SPSS (v. 24.0); * $p < 0.05$; ** $p < 0.01$, ND: no enough data for statistics, ^c; not included in the statistics, ^d; n = 4, ^e; n = 3. Idiopathic anaphylaxis and other causes are excluded.




FIGURE 2 Progression findings from patients with food anaphylaxis from T1 at the acute phase to T2 at recovery using LC-MS in positive mode. (A) PCA and (B) OPLSDA cross-validated models for food anaphylaxis between T1 and T2; $n = 6$; log transformation and centre scaling was used for the models. (C) Prediction model using the samples of food anaphylaxis at T1 (blue circle) and T2 (green circle) to predict patients allergic to drugs at T1. Patients allergic to antibiotics are depicted in red circles, whereas allergic patients to NSAIDs drugs, iomeprol and carmellosa were painted in purple. (D) Heat map using hierarchical clustering of the samples of food anaphylaxis at T1 and T2 (represented in columns) and features (in rows) using signals showing statistically significant differences ($n = 73$) from LC-MS in positive mode. Red cells represent higher levels of the specific metabolite in that sample, whereas blue cells represent lower levels. Samples and metabolites are clustered according to their similarity. Wilcoxon signed-rank test with a Benjamini-Hochberg correction was used to detect statistical significance ($p < 0.05$). Metabolites are defined as mass (Da)/retention time (min). (E) Trajectories of significant identified metabolites in food anaphylaxis group between T1 and T2; * $p < 0.05$

3.5 | Metabolic differences due to severity at different time-points T1 and T0

Finally, metabolic differences due to severity during the anaphylactic episode (at T1) and at the basal point (at T0) were analysed independently.

Using univariate analysis, we observed that at the moment of the anaphylactic reaction (T1), 7 metabolites from both techniques (LC-MS and $^1\text{H-NMR}$) were significantly higher in the severe group compared to the moderate group. These metabolites included cortisol, glucose, lipids ($-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-$), lipids ($-\text{CH}=\text{CH}-$) and lipoprotein methyl group signal (Table S6).

Likewise, at the basal time-point (T0), the levels of 10 metabolites using both techniques were significantly higher in the severe group compared to the moderate group such as oleamide, PC(14:0/20:4), lactate, lipids ($-\text{CH}_2-\text{CH}=\text{CH}-$), lipids ($-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-$) and lipids ($-\text{CH}=\text{CH}-$). Meanwhile, betaine and cortisol were lower (Table S7). Trajectories of these metabolites showed that most of them are increased in severe group regardless of the time-point (T1 or T0, Figure 4).

4 | DISCUSSION

The increasing prevalence of anaphylaxis reactions points out to an urgent need for progress in the search of biomarkers for early diagnosis and accurate therapy. Studies of anaphylaxis in humans are still one of the greatest challenges in allergy research, and to date, they are very limited due to the clear difficulties they entail.

In this exploratory study, most anaphylactic cases occurred in women. They were mostly attributed to drugs, being graded as the most serious followed by foods. Drug mediated reactions were more common in elderly patients. All these observations match with previous studies of anaphylaxis.³⁵ Regarding the clinical parameters, tryptase was not elevated in all the cases (88% in drug and 66% in food anaphylaxis) as has been previously reported.¹⁵ Interestingly, patients with reactions classified as idiopathic did not show elevation of tryptase during the reaction, explaining the heterogeneity of the trigger mechanism. Other clinical parameter was the number of leucocytes, which was significantly increased in food compared to drug anaphylaxis. This fact also has already been described by other authors.³⁶ Further studies are needed to clarify this result.

Regarding food anaphylaxis, we observed a clear metabolic pattern during the time of the anaphylactic reaction ('T1 vs T2'), which was not observed in drug or food + drug anaphylaxis. This finding could be related to different mechanisms of action triggered by different allergens. Food anaphylaxis reactions, which are mainly IgE-mediated, were confirmed by sIgE measures, whereas the mechanisms of drug-triggered reactions are described to be more heterogeneous.³⁷ This fact was confirmed with the prediction of the well-characterized drug anaphylaxis of β -lactam and NSAIDs. β -lactam antibiotic-triggered reactions, which are known to be IgE-mediated, were clustered together within one of the groups of food anaphylaxis model (T1 and T2).

Other IgE-independent reactions like those caused by NSAIDs were not clustered within the food model. However, the mechanisms of other drug-triggers like iomeprol, carmellose and moxifloxacin are not clearly defined.³⁸⁻⁴³ Iomeprol (not classified with food anaphylaxis with a prediction score of 73%) has been strongly suggested to trigger IgE-mediated hypersensitivity by a diagnostic workup using basophil activation test.^{39,40} Carmellose (not classified with food anaphylaxis with a prediction score of 54%) was reported having an unclear mechanism.³⁸ Finally, moxifloxacin (classified with food anaphylaxis prediction score of 91%) follows a mixed IgE and MRGPRX2-mediated mechanisms.⁴¹⁻⁴³

The metabolic changes observed in food anaphylaxis at 'T1 vs T2' were that phospholipids significantly decreased, while choline, a substrate of PCs, was found increased, all at T1. These were mainly PCs, from which palmitic acid (C16:0), which displays anti-inflammatory activities, and palmitoleic acid (C16:1), that enhances the inflammatory reactions, were the most frequent fatty acids chains contained in their structure.⁴⁴⁻⁴⁷ These fatty acids are freed from PCs by the action of the phospholipase A2 enzyme (PLA2), which promotes mast cells maturation.⁴⁸ This suggests that these PCs are key regulators in the acute phase.

To complement this, we found increased levels during the acute reaction (T1) of (1) acetate, which is released in catabolic and metabolic stress conditions.⁴⁹ (2) Glutamine, which is essential during catabolic situations, as the rate of glutamine consumption by all immune cells is similar or greater than glucose.⁵⁰ Moreover, glutamine promotes enterocyte proliferation, regulates tight junction proteins, suppresses proinflammatory signalling pathways and confers protection against apoptosis and cellular stresses during normal and pathological conditions.⁵¹ It is known that during anaphylaxis, mast cells, basophils and neutrophils induce hypotension, vascular hyper-permeability and an endothelial production of nitric oxide (NO).⁵² (3) Phenylalanine can be involved in NO production, reducing superoxide species and enhancing vascular function.⁵³ (4) Histidine is the precursor of histamine which is synthesized by the action of the histidine decarboxylase enzyme inside mast cells and basophils.⁵⁴ As histamine is released in T1 when the patient is recovered at T2, histidine would decrease since it could be used to replenish histamine in the mast cells granules.

To sum up, all these metabolic changes seem to be a reflection of anaphylaxis and suggest a rapid metabolic response to a series of defined innate defensive mechanisms and the elevated catabolism triggered in the first moments of the anaphylactic episode.

The moderate anaphylactic reactions were characterized by a decrease in several PCs at T1. The most frequent fatty acyl chains of these PCs were palmitoleic acid (C16:1), docosahexaenoic acid (C22:6; DHA), precursors of anti-inflammatory specialized pro-resolving mediators and arachidonic acid (C20:4; AA), related to inflammatory processes.^{44,55} Furthermore, we detected increased levels of branched-chain amino acids (BCAA: leucine, isoleucine and valine) at T1. Elevated BCAA levels generate inflammation and oxidative stress in endothelial cells via mTORC1 pathway, thereby facilitating inflammatory cells adhesion and endothelial dysfunction.⁵⁶ Another metabolite which was increased at T1 was arginine.





FIGURE 3 Progression findings from patients with moderate anaphylaxis from T1 at the acute phase to T2 at recovery using the ^1H -NMR data. (A) PCA and (B) OPLSDA cross-validated models for moderate anaphylaxis between T1 and T2; $n = 8$; Pareto scaling was used for the models using the ^1H -NMR data. (C) Heat map using hierarchical clustering of the samples of moderate anaphylaxis at T1 and T2 (represented in columns) and buckets (in rows) including significant buckets ($n = 111$) from ^1H -NMR analysis. Red cells represent higher levels of the specific NMR spectra region in that sample, whereas blue cells represent lower levels. Samples and features are clustered according to their similarity. Wilcoxon signed-rank test with a Benjamini-Hochberg correction was used to detect statistical significance ($p < 0.05$). (D) Trajectories of significant identified metabolites in moderate anaphylaxis group between T1 and T2; * $p < 0.05$

During anaphylaxis, histamine binds to H_1 receptors. This stimulates endothelial cells to convert the amino acid arginine into NO.⁴ These observed results point to an alteration of the energy metabolism. In particular, an increase in lactate, acetate and creatinine was

detected at T1. High amounts of lactate, the resulting product of anaerobic glycolysis, are produced by innate immune cells during inflammatory activation.⁵⁷ Additionally, an increase in proline at T1 was observed. Recent findings suggest that proline is a stress

(A)

During the anaphylaxis acute moment T1



(B)

During the basal time T0




FIGURE 4 Trajectories of significant identified metabolites between moderate and severe groups at specific time-points: (A) at T1 in the acute phase and (B) at T0 in the basal point using the data from all techniques. Mann-Whitney *U* test with a Benjamini-Hochberg correction was used to detect statistical significance ($p < 0.05$)

substrate in inflammation, as it is used to generate superoxide radicals which initiate apoptosis, as well as an energy source.⁵⁸ Finally, increases in glutamine, phenylalanine and choline were also observed at T1 and have already been described for the model of food anaphylaxis 'T1 vs T2'.

To sum up, moderate anaphylactic reactions appear to be the result of proinflammatory metabolites, and some of them could be involved in the endothelium and immune cell participation.

On the other hand, for severe anaphylactic reactions between 'T1 vs T2', the AA fatty acyl chain of the PC could point to a more sustained inflammation by the severe individuals. This might be associated with a higher difficulty of the inflammatory system to recover and/or the heterogeneity of the patients regarding their recovery at T2.

If there are still many questions regarding the underlying mechanisms of action of anaphylaxis, the factors that determine their severity present an equal or even greater challenge. We analysed the metabolic differences between moderate and severe groups in the acute phase of the reaction (T1). The severe group presented higher levels compared to the moderate group of (1) glucose, which supports the enhanced cellular metabolism of the immune system, (2) lipids and lipoproteins, suggest a higher cell signalling and energy consumption and (3) cortisol—an endogenous metabolite with strong anti-inflammatory properties—which points to the mobilization of glucose reserves for energy and inflammatory modulation.

Analysis of samples at basal time (T0) was carried out to investigate risk factors for severe anaphylaxis. Severe reactions showed higher levels of glucose, lipids and oleamide, and lower amounts of cortisol and betaine compared to moderate reactions during the basal phase. Oleamide has been described to have anti-inflammatory and anti-allergenic functions in both *in vivo* and *in vitro* models.^{59–61} The higher levels of oleamide detected in severe patients, months after the anaphylactic reaction, could suggest a protective metabolic state. Alternatively, betaine—an important tissue osmolyte—is *de novo* biosynthesized based on the choline oxidation, which is a precursor of PCs.^{62,63} This would explain the low levels of betaine in patients who suffered severe reactions and who maintain a high level of serum phospholipids and therefore a lower use of choline to generate betaine.

The limitations of carrying out non-targeted metabolomic studies on anaphylaxis in a real-life set-up are unavoidable. As such, medication is present at one or another time before sample collection (T1 or T2). However, as not all the patients received the same emergency medication, the changes that were observed regarding the triggers or severity at T1 vs T2 can be truly associated with the disease. Another limitation is the lack of homogeneity among the cases by the trigger, age range and food intake which are factors that cannot be controlled in an emergency set-up. Complementary comparisons such as T1 vs T0 and food vs drug at T0 are of high interest and could be addressed in future studies following other experimental designs. Further validation in a bigger cohort will be necessary to confirm

our results, avoiding any possible bias between study groups and increasing the power of the analysis.

The results of this exploratory study provide the first evidence that different anaphylactic triggers or severity induce differential metabolic changes along time or at specific time-point, respectively. These findings suggest to some extent, the immunological memory also extends to the metabolism of patients, especially those who experienced severe anaphylaxis. Despite the need for additional research to confirm these results, the metabolites identified in our exploratory study could shed light on the prediction of the risk of a severe anaphylaxis.

ACKNOWLEDGEMENTS

We would like to thank all institutions and the hospital involved: Emergency, Anesthesiology and specially to Allergy Department of Hospital Universitari I Politècnic La Fe (Valencia), Drug Discovery Unit and Metabolomic Department of Health Research Institute La Fe (Valencia, Spain), Institute of Applied Molecular Medicine (IMMA, San Pablo CEU University, Madrid), Centre for Metabolomics and Bioanalysis (CEMBIO, San Pablo CEU University, Madrid), Hospital Central de la Cruz Roja (Faculty of Medicine, Alfonso X El Sabio University) and IIS-Fundación Jiménez Díaz.

CONFLICT OF INTEREST

Domingo Barber has received consultancy fees from ALK and Aimmune therapeutics companies. The rest of the authors have no conflict of interest. All authors have read and approved the manuscript.

AUTHOR CONTRIBUTION

DHFR was the PI and together with CP-C, AP-L and LP-C designed and supervised the research. MR, DO and LT performed the LC-MS based metabolomic analysis, data treatment and identification of metabolites. LP-C and AR-B performed the NMR metabolomic analysis. DO, LT, VE, CB, JLL, DB and AV contributed to the metabolomics interpretation. CP-C, JM-G, EI-E, RL-S and DHFR included all study patients. DB and AV supervised statistical analysis. All authors contributed to the writing of the manuscript and have given approval to the final version of the manuscript.

ETHICS APPROVAL

The ethical committee from 'Instituto de Investigación Sanitaria La Fe' approved the study protocol signed by the general director José Vicente Castell Ripoll and the board president Rafael Botella Estrada.

ORCID

David Obeso  <https://orcid.org/0000-0001-7875-7327>

José Julio Laguna  <https://orcid.org/0000-0001-5909-8979>

Domingo Barber  <https://orcid.org/0000-0002-5488-5700>

Alma Villaseñor  <https://orcid.org/0000-0002-6652-2739>

REFERENCES

- Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. *World Allergy Organ J*. 2020;13(10):100472.
- Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. *Clin Exp Allergy*. 2015;45(6):1027-1039.
- Brown SG, Stone SF, Fatovich DM, et al. Anaphylaxis: clinical patterns, mediator release, and severity. *J Allergy Clin Immunol*. 2013;132(5):1141-1149.e5.
- Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. *J Allergy Clin Immunol*. 2002;110(3):341-348.
- Ogawa Y, Grant JA. Mediators of Anaphylaxis. *Immunol Allergy Clin N Am*. 2007;27(2):249-260.
- Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. *J Allergy Clin Immunol*. 2017;140(2):335-348.
- Escribese MM, Rosace D, Chivato T, Fernández TD, Corbí AL, Barber D. Alternative anaphylactic routes: the potential role of macrophages. *Front Immunol*. 2017;8:515.
- Finkelman FD. IgE-Dependent and Independent Effector Mechanisms in Human and Murine Anaphylaxis. In: Castells M, ed. *Anaphylaxis and Hypersensitivity Reactions*. Humana Press; 2011:127-144. https://doi.org/10.1007/978-1-60327-951-2_8
- Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. *J Allergy Clin Immunol*. 2016;137(6):1674-1680.
- Muñoz-Cano R, Picado C, Valero A, Bartra J. Mechanisms of anaphylaxis beyond IgE. *J Invest Allergol Clin Immunol*. 2016;26(2):73-82. quiz 2p following 3.
- Jonsson F, de Chaisemartin L, Granger V, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. *Sci Transl Med*. 2019;11(500):eaat1479.
- Galli SJ. The TWEAK/Fn14 axis in anaphylactic shock. *J Allergy Clin Immunol*. 2020;145(2):491-493.
- Simons FE. 9. Anaphylaxis. *J Allergy Clin Immunol*. 2008;121(2 Suppl):S402-S407. quiz S20.
- Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol*. 2013;131(1):144-149.
- Srivastava S, Huissoon AP, Barrett V, et al. Systemic reactions and anaphylaxis with an acute serum tryptase ≥ 14 $\mu\text{g/L}$: retrospective characterisation of aetiology, severity and adherence to National Institute of Health and Care Excellence (NICE) guidelines for serial tryptase measurements and specialist referral. *J Clin Pathol*. 2014;67(7):614-619.
- Brown SG, Blackman KE, Hedde RJ. Can serum mast cell tryptase help diagnose anaphylaxis? *Emerg Med Australas*. 2004;16(2):120-124.
- Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. *Annals of Allergy, Asthma & Immunology*. 2015;115(5):341-384. <http://dx.doi.org/10.1016/j.anai.2015.07.019>
- Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. *Allergy*. 2014;69(8):1026-1045.
- Parameters JTFoP, American Academy of Allergy Atal, American College of Allergy Atal, Joint Council of Allergy Atal. The diagnosis and management of anaphylaxis: an updated practice parameter. *J Allergy Clin Immunol*. 2005;115(3 Suppl 2):S483-523.
- Villaseñor A, Rosace D, Obeso D, et al. Allergic asthma: an overview of metabolomic strategies leading to the identification of biomarkers in the field. *Clin Exp Allergy*. 2017;47(4):442-456.
- Barber D, Villaseñor A, Escribese MM. Metabolomics strategies to discover new biomarkers associated to severe allergic phenotypes. *Asia Pac Allergy*. 2019;9(4):e37.
- Carraro S, Giordano G, Reniero F, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. *Allergy*. 2013;68(1):110-117.
- Jung J, Kim SH, Lee HS, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. *Clin Exp Allergy*. 2013;43(4):425-433.
- Crestani E, Harb H, Charbonnier LM, et al. Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma. *J Allergy Clin Immunol*. 2020;145(3):897-906.
- Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. *J Asthma Allergy*. 2018;11:121-142.
- Hu X, Wu GP, Zhang MH, et al. GC-MS-based metabolic profiling reveals metabolic changes in anaphylaxis animal models. *Anal Bioanal Chem*. 2012;404(3):887-893.
- Kong J, Chalcraft K, Mandur TS, et al. Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. *Allergy*. 2015;70(5):495-505.
- Chalcraft KR, Kong J, Wasserman S, Jordana M, McCarry BE. Comprehensive metabolomic analysis of peanut-induced anaphylaxis in a murine model. *Metabolomics*. 2014;10(3):452-460. <http://dx.doi.org/10.1007/s11306-013-0589-7>
- Brown SG. Clinical features and severity grading of anaphylaxis. *J Allergy Clin Immunol*. 2004;114(2):371-376.
- Peña-Bautista C, Roca M, Hervás D, et al. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. *J Proteomics*. 2019;200:144-152. <http://dx.doi.org/10.1016/j.jpro.2019.04.008>
- Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protoc*. 2007;2(11):2692-2703.
- Dona AC, Jiménez B, Schäfer H, et al. Precision High-Throughput Proton NMR Spectroscopy of Human Urine, Serum, and Plasma for Large-Scale Metabolic Phenotyping. *Anal Chem*. 2014;86(19):9887-9894. <http://dx.doi.org/10.1021/ac5025039>
- Gil de la Fuente A, Godzien J, Fernández López M, Rupérez FJ, Barbas C, Otero A. Knowledge-based metabolite annotation tool: CEU Mass Mediator. *J Pharm Biomed Anal*. 2018;154:138-149.
- Gil-de-la-Fuente A, Godzien J, Saugar S, et al. CEU mass mediator 3.0: A metabolite annotation tool. *J Proteome Res*. 2019;18(2):797-802.
- Aurich S, Dolle-Bierke S, Francuzik W, et al. Anaphylaxis in elderly patients-data from the european anaphylaxis registry. *Front Immunol*. 2019;10:750.
- Kim SY, Kim MH, Cho YJ. Different clinical features of anaphylaxis according to cause and risk factors for severe reactions. *Allergol Int*. 2018;67(1):96-102.
- Kuruvilla M, Khan DA. Anaphylaxis to drugs. *Immunol Allergy Clin North Am*. 2015;35(2):303-319.
- Niwa Y, Hayama K, Tagui T, et al. Case of anaphylaxis due to carmellose sodium. *J Dermatol*. 2020;47(1):e15-e17.
- Bircher AJ, Izakovic J. Oral tolerance of carboxymethylcellulose in patients with anaphylaxis to parenteral carboxymethylcellulose. *Ann Allergy Asthma Immunol*. 2004;92(5):580-581.
- Philippe E, Sabato V, Bridts C, De Clerck L, Ebo D. Basophil activation in the diagnosis of life-threatening hypersensitivity reaction to iodinated contrast media: a case report. *Acta Clin Belg*. 2013;68(2):140-142.
- McGee EU, Samuel E, Boronea B, Dillard N, Milby MN, Lewis SJ. Quinolone Allergy. *Pharmacy (Basel)*. 2019;7(3):97.
- Campi P, Pichler WJ. Quinolone hypersensitivity. *Curr Opin Allergy Clin Immunol*. 2003;3(4):275-281.
- Liu R, Hu S, Zhang Y, et al. Mast cell-mediated hypersensitivity to fluoroquinolone is MRGPRX2 dependent. *Int Immunopharmacol*. 2019;70:417-427.
- Astudillo AM, Balboa MA, Balsinde J. Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in activated cells leading to polyunsaturated fatty acid mobilization. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019;1864(6):772-783.

45. Korbecki J, Bajdak-Rusinek K. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms. *Inflamm Res*. 2019;68(11):915-932.
46. Tzeng HT, Chyuan IT, Chen WY. Shaping of innate immune response by fatty acid metabolite palmitate. *Cells*. 2019;8(12):1633.
47. Riera-Borrull M, Cuevas VD, Alonso B, et al. Palmitate conditions macrophages for enhanced responses toward inflammatory stimuli via JNK activation. *J Immunol*. 2017;199(11):3858-3869.
48. Murakami M, Taketomi Y. Secreted phospholipase A2 and mast cells. *Allergol Int*. 2015;64(1):4-10.
49. Balmer ML, Ma EH, Bantug GR, et al. Memory CD8 + T Cells Require Increased Concentrations of Acetate Induced by Stress for Optimal Function. *Immunity*. 2016;44(6):1312-1324. <http://dx.doi.org/10.1016/j.immuni.2016.03.016>
50. Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. *Nutrients*. 2018;10(11):1564.
51. Perna S, Alalwan TA, Alaali Z, et al. The role of glutamine in the complex interaction between gut microbiota and health: a narrative review. *Int J Mol Sci*. 2019;20(20):5232.
52. Nakamura T, Murata T. Regulation of vascular permeability in anaphylaxis. *Br J Pharmacol*. 2018;175(13):2538-2542.
53. Heikal L, Starr A, Hussein D, et al. L-phenylalanine restores vascular function in spontaneously hypertensive rats through activation of the GCH1-GFRP complex. *JACC Basic Transl Sci*. 2018;3(3):366-377.
54. Hirasawa N. Expression of histidine decarboxylase and its roles in inflammation. *Int J Mol Sci*. 2019;20(2):376.
55. Sokolowska M, Rovati GE, Diamant Z, et al. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. *Allergy*. 2021;76(1):114-130. <http://dx.doi.org/10.1111/all.14295>
56. Zhenyukh O, Gonzalez-Amor M, Rodrigues-Diez RR, et al. Branched-chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and inflammation. *J Cell Mol Med*. 2018;22(10):4948-4962.
57. Ratter JM, Rooijackers HMM, Hooiveld GJ, et al. In vitro and in vivo effects of lactate on metabolism and cytokine production of human primary PBMCs and monocytes. *Front Immunol*. 2018;9:2564.
58. Phang JM, Pandhare J, Liu Y. The metabolism of proline as microenvironmental stress substrate. *J Nutr*. 2008;138(10):2008S-2015S.
59. Kita M, Ano Y, Inoue A, Aoki J. Identification of P2Y receptors involved in oleamide-suppressing inflammatory responses in murine microglia and human dendritic cells. *Sci Rep*. 2019;9(1):3135.
60. Moon SM, Lee SA, Hong JH, Kim JS, Kim DK, Kim CS. Oleamide suppresses inflammatory responses in LPS-induced RAW264.7 murine macrophages and alleviates paw edema in a carrageenan-induced inflammatory rat model. *Int Immunopharmacol*. 2018;56:179-185.
61. Sudhahar V, Shaw S, Imig JD. Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. *Eur J Pharmacol*. 2009;607(1-3):143-150.
62. Craig SA. Betaine in human nutrition. *Am J Clin Nutr*. 2004;80(3):539-549.
63. Zhao G, He F, Wu C, et al. Betaine in inflammation: mechanistic aspects and applications. *Front Immunol*. 2018;9:1070.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Perales-Chorda C, Obeso D, Twomey L, et al. Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers. *Clin Exp Allergy*. 2021;00:1-15. <https://doi.org/10.1111/cea.13991>

SUPPLEMENTARY INFORMATION

Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers

Carolina Perales-Chorda, MD^{1*}, David Obeso, PhD^{2,3*}, Laura Twomey, BSc^{2,3}, Ayelén Rojas-Benedicto, BSc⁴, Leonor Puchades-Carrasco, PhD⁴, Marta Roca, PhD⁵, Antonio Pineda-Lucena, PhD^{4,6}, José Julio Laguna, MD^{7,8}, Coral Barbas, PhD³, Vanesa Esteban, PhD^{8,9}, Jaume Martí-Garrido, MD¹, Ethel Ibañez-Echevarria, MD¹, Ramón López-Salgueiro, MD¹, Domingo Barber, PhD², Alma Villaseñor, PhD^{2#}, Dolores Hernández Fernández de Rojas, MD, PhD^{1#}.

¹Allergy Department of Hospital Universitari i Politècnic La Fe, Valencia. Spain.

²IMMA, Instituto de Medicina Molecular Aplicada, Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte. Madrid. Spain.

³CEMBIO, Centre for Metabolomics and Bioanalysis, Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte. Madrid. Spain.

⁴Drug Discovery Unit, Health Research Institute La Fe (Valencia, Spain).

⁵Analytical Unit, Health Research Institute Hospital La Fe, Valencia, Spain.

⁶Molecular Therapeutics Program, Center for Applied Medical Research, University of Navarra (Pamplona, Spain).

⁷Allergy Unit, Allergo-Anaesthesia Unit, Hospital Central de la Cruz Roja.

⁸Faculty of Medicine and Biomedicine, Alfonso X El Sabio University.

⁹Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.

^{*}, [#] These Authors have equally contributed.

Corresponding author:

Dolores Hernández Fernández de Rojas, MD, PhD

Allergy Research Group - IIS - Hospital Universitari i Politècnic La Fe

Avinguda de Fernando Abril Martorell, 106, 46026 València, Valencia, España.

Tlf: 91 372 47 00 ext. 4662

E-mail: hernandez_dol@gva.es

This file includes:

Part 1. Detailed procedure for sample collection.

Part 2. Detailed description of sample preparation, instrumental description, data pre-treatment for metabolomics analyses and statistical analysis.

Supplementary Figure 1S:

Figure 1S. Unsupervised PCA models showing the quality of the data for LC-MS: A)ESI (+) and B)ESI (-). (Key: QC injections (●; dot), samples (●; grey circle). Models were UV scaled and included 228 and 334 features for LC-MS+ and LC-MS-, respectively.

Supplementary Table S1 to S6:

Table 1S. Patient complementary information for medication and time of sample collection.

Table 2S. Results from the OPLS-DA prediction model.

Table 3S. Significant metabolites identified for Food anaphylaxis between T1 and T2 time points.

Table 4S. Significant metabolites identified for Moderate anaphylaxis between T1 and T2 time points.

Table 5S. Significant metabolites identified for Severe anaphylaxis between T1 and T2 time points.X

Table 6S. Significant metabolites identified for Severe vs Moderate anaphylaxis at T1 time point.X

Table 7S. Significant metabolites identified for Severe vs Moderate anaphylaxis at T0 time point.X

PART 1. Detailed procedure for sample collection.

For the Standardized Operation Process for sample collection. Blood samples were collected into BD Vacutainer® SST™ Advance Tube (BD Biosciences, Spain). After collection, the blood was allowed to clot at 4°C for 30 min, followed by centrifugation at 1600 rpm for 15 minutes in a refrigerated centrifuge at 4°C. The resulting supernatant was immediately transferred into clean tubes and store at -80C until analysis.

PART 2. Detailed description of sample preparation, instrumental description, data pre-treatment for metabolomics analyses.

UPLC-Q-ToF MS analysis

Chemicals and reagents

All reagents used were of analytical grade. Optimum LC-MS grade acetonitrile, formic acid (99%) and ultrapure water were obtained from Merk (Darmstadt, Germany). Reserpine, leucine, enkephaline, caffeine-d9 and phenylalanine-d5 used as internal standards were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Sample preparation

After thawing the samples, 150 µL of cold acetonitrile (0.1% formic acid, v/v) was added to 50 µL of serum, vortex and kept at -20°C for 30 min for protein precipitation. Then, 25 µL of cleaned supernatant were transferred to a 96 well-plate for UPLC-MS analysis. Finally, 125 µL of H₂O (0.1% formic acid, v/v), and 2 µL of internal standard (IS) mix solution, containing reserpine, leucine, enkephaline, caffeine-d9 and phenylalanine-d5 in H₂O:CH₃OH (1:1, 0.1% v/v formic acid) at 20 µM were added to each sample. Blank samples were prepared by replacing serum by ultrapure H₂O in order to identify potential artefacts from the tube, reagents and other materials. A quality control (QC) was prepared by mixing 10 µL from each prepared sample. Samples were randomly injected in the chromatographic system (UPLC-ToF-MS) injection a QC every 6 serum samples in order to avoid intra-batch variability, as well as to enhance quality and reproducibility. Blank analysis was performed at the beginning and at end of the sequence. Sample stability and analytical drift were investigated through the IS intensities.

UPLC-Q-ToF MS characteristics

The metabolomic analysis was carried out using an Ultra-Performance Liquid Chromatography (UPLC) system coupled to an iFunnel quadrupole time of flight (Q-ToF) Agilent 6550 mass spectrometer (Agilent Technologies, CA, USA). The chromatographic separation was performed by using an UPLC BEH C18 (100 x 2.1 mm, 1.7 μ m, Waters, Wexford, Ireland) column from Waters (Wexford, Ireland). Autosampler and column temperatures were set to 4°C and 40°C, respectively, and the injection volume was 5 μ L. Mobile phase A and B consisted of H₂O and acetonitrile, respectively, both containing 0.1% formic acid. The gradient lasted 14 minutes at a flow rate of 400 μ L min⁻¹. The mobile phase A was maintained at 98% for 1 min, and then decreased until 75% in 2 minutes, 50% in 3 minutes and 5% in 3 more minutes. 95% of mobile phase B was held for 3 min and then, a 0.55 min gradient was used to return to the initial conditions, which were held for 2.5 min to full column recovery. Full scan MS data from 50 to 1700 m/z with a scan frequency of 6 Hz was collected both in positive and negative electrospray ionization modes (ESI + and ESI -, respectively). The following ESI parameters were used: gas temperature, 200°C; drying gas, 14 l min⁻¹; nebulizer, 60 psi; sheath gas temperature, 350°C; sheath gas flow, 11 l min⁻¹. Automatic MS spectra recalibration was carried out introducing a reference standard containing m/z 149.0233, m/z 121.0508 and m/z 922.0097 into the source via a reference sprayer valve during the analysis.

Data pre-processing

Data processing was done by using an in-house R (v.3.6.1) processing script with XCMS and CAMERA packages for peak detection, noise filtering and peak alignment. Parameters selected for peak peaking and peak grouping were based on previous instrumental data analysis experience (1). The resulting data matrix was generated including molecular features (m/z -retention time), sample ID (observations) and peak intensities. The dataset was then filtered according to the quality assurance criteria of coefficient of variation <30% in QC samples and the presence of the variable in 60% of the samples in at least one of the compared groups. Prior to statistical analysis, normalization using QC-SVRC algorithm(2, 3) was carried out. This normalization uses the information contained in the QCs to correct the drift of the MS signal within the batch. After data pre-processing, each metabolic profile was characterized by 1337 and 831 chemical signals for LC-MS in positive and negative ESI modes, respectively.

LC-MS Metabolite identification

Initially, a tentative identification was performed in all the significant features by searching the accurate masses against the online available databases such as KEGG, METLIN, LipidMaps and HMDB using an online advanced software called CEU Mass Mediator tool (4, 5). After that, ID was confirmed through LC-MS/MS experiments by using a QTOF (model 6550, Agilent). Experiments were reproduced in same identical chromatographic conditions as the primary analyses. Ions were targeted using the narrow m/z window (1.3 Da) and 20 eV of energy for fragmentation on the quadrupole at the retention time (RT) previously determined. Comparison of the structure proposed against the obtained fragments led to the confirmation of the identity. Finally, those compounds with an available commercial standard were confirmed by comparison of RT and fragmentation pattern distribution.

¹H-NMR analysis

Sample preparation and NMR spectra acquisition

At the time of ¹H-NMR analysis, frozen serum samples were thawed on ice. Then, 300 µL of serum sample were added to 300 µL of NMR buffer (4.6mM TSP, 140mM Na₂HPO₄, 0.04% NaN₃ at pH 7.4 in D₂O). Finally, 550 µL of sample were transferred to a 5 mm NMR tube for analysis.

The NMR spectra were acquired at 310 K on a Bruker 500MHz spectrometer using a 5 mm TXI probe. A CPMG (Carr-Purcell-Meiboom-Gill) spin-echo pulse sequence was collected for each sample. The ¹H-NMR spectra were acquired for a total of 256 scans and 61 K data points over a spectral width of 20 ppm. A 4-s relaxation delay was included between free induction decays (FIDs). Then, serum spectra were multiplied by a line-broadening factor of 1 Hz and Fourier transformed. Finally, all spectra were automatically phase, baseline corrected and referenced to the alanine signal at 1.47 ppm using TopSpin 3.5pl6 (Bruker Biospin).

NMR data analysis

After acquisition, spectra were binned using AMIX 3.9.15 (Bruker Biospin) into 0.01 ppm wide buckets over the spectral region δ 0.5–8.5 ppm and integrated using sum of absolute intensities.

The residual water (δ 5.173 – 4.339 ppm) and urea (δ 6.2 – 5.6 ppm) signal regions were excluded from further analysis to avoid interferences. After data pre-processing, each metabolic profile was characterized by 800 buckets.

Assignment of NMR signals and metabolite quantification

NMR signals corresponding to the metabolites most relevant for the classification of samples in the multivariate statistical analysis, were assigned using the Human Metabolome Database (HMDB) and the Biological Magnetic Resonance Data Bank (BMRB). The variable size bucketing method from AMIX was used to integrate the integral value corresponding to each metabolite signal.

Statistical analyses

To investigate differences between time points (T1 vs T2) the non-parametric Wilcoxon signed-rank test with a Benjamini-Hochberg (BH) correction were used. Additionally, significant differences among severity (severe vs moderate) were analyzed using U-Mann Whitney test with a BH p -value correction. Both using Matlab R2015a (Mathworks) software and the statistical significance was set at 95% level ($p < 0.05$).

Multivariate analysis was performed using SIMCA P+14.0 (Umetrics, Umeå, Sweden). Principal component analysis (PCA) was applied to observe data patterns, while orthogonal least square-discriminant analysis model (OPLS-DA) was used to assess the separation of groups. Robustness of the models was evaluated based on R^2 (explained variance) and Q^2 (capability of prediction) scores(6-8).

Regarding the comparisons, 5 pair-wise comparisons were made: 1) Food T1 vs T2 (Table 3S), 2) Moderate T1 vs T2 (Table 4S), 3) Severe T1 vs T2 (Table 5S), 4) Moderate vs Severe at T1 (Table 6S) and 5) Moderate vs Severe at T0 (Table 7S).

Figure 1S. Unsupervised PCA models showing the quality of the data for LC-MS: A)ESI (+) and B)ESI (-). (Key: QC injections (●; dot), samples (●; grey circle). Models were UV scaled and included 228 and 334 features for LC-MS+ and LC-MS-, respectively.




Table 1S. Complementary information for patient medication and time of sample collection.

Anaphylaxis trigger	Code	Sample collection [#]		Treatment before sample collection ^{&}
		Time	Time (h:hours/m:months)	
FOOD	P2	T0	2-3 m	No treatment
		T1	2 h	Epinephrine + Antih1 + Corticosteroids
		T2	4 h	Epinephrine + Antih1 + Corticosteroids
FOOD	P8	T0	2-3 m	No treatment
		T1	1 h	No treatment
		T2	3 h	Antih1 + Corticosteroids
FOOD	P9	T1	0.5 h	Epinephrine
		T2	2.5 h	Epinephrine + Corticosteroids
FOOD	P10	T0	2-3 m	Antih1 + Corticosteroids
		T1	2 h	Epinephrine + Antih1 + Corticosteroids
		T2	4 h	Epinephrine + Antih1 + Corticosteroids
FOOD	P15	T0	2-3 m	No treatment
		T1	0.5 h	No treatment
		T2	2.5 h	Epinephrine + Antih1 + Corticosteroids
FOOD	P17	T0	2-3 m	No treatment
		T1	0.5 h	No treatment
		T2	2.5 h	Epinephrine + Antih1 + Corticosteroids
DRUG	P1	T0	2-3 m	No treatment
		T1	1 h	Triamcinolone + Mepivacaine + Benzyl alcohol + Sodium carmellose; No treatment
		T2	3 h	Antih1 + Corticosteroids + Ranitidine
DRUG	P3	T0	2-3 m	No treatment
		T1	1 h	lomeprol; Corticosteroids
DRUG	P4	T0	2-3 m	No treatment
		T1	0.5 h	Amoxicillin/Clavulanic acid; Corticosteroids

		T2	2.5 h	Antih1 + Corticosteroids + Salbutamol
DRUG	P7	T0	2-3 m	Corticosteroids + Linezolid
		T1	2 h	Moxifloxacin; Corticosteroids
		T2	4 h	Antih1 + Corticosteroids + Ranitidine
DRUG	P12	T0	2-3 m	No treatment
		T2	3 h	Metamizole; Antih1 + Corticosteroids + Ranitidine
DRUG	P13	T0	2-3 m	No treatment
		T1	1 h	Omeprazole + Diclofenac; No treatment
		T2	2.5 h	Epinephrine + Antih1 + Corticosteroids
DRUG	P14	T0	2-3 m	No treatment
		T1	0.5 h	Ampicillin; Antih1 + Corticosteroids
DRUG	P16	T0	2-3 m	No treatment
		T1	1 h	Amoxicillin/Clavulanic acid; Ondansetron + Fentanyl + Epinephrine + Antih1 + Corticosteroids
		T2	2.5 h	Epinephrine + Antih1 + Corticosteroids
DRUG	P18	T0	2-3 m	No treatment
		T1	2 h	Celecoxib; Epinephrine + Antih1 + Corticosteroids
		T2	4 h	Epinephrine + Antih1 + Corticosteroids
IDIOPATIC	P5	T1	2 h	Antih1 + Corticosteroids
		T2	4 h	Antih1 + Corticosteroids
IDIOPATIC	P6	T0	2-3 m	Pantoprazole
		T1	0.5 h	Amoxicillin+ Fentanyl + Propofol + Rocuronium; Antih1 + Corticosteroids
		T2	4 h	Antih1 + Corticosteroids
IDIOPATIC	P11	T0	2-3 m	No treatment
		T1	2 h	Bismuth subsalicylate + Metronidazole + Tetracycline + Lactose + Potassium; Epinephrine + Corticosteroids
		T2	4 h	Epinephrine + Corticosteroids

Antih1; antihistaminic H1 receptor, #this the time interval between reaction onset and T1, T2 and T0 sampling; &the “;” separates the drug taken by the patient and the rescued treatment given at emergency room.

Table 2S. Results from the OPLS-DA prediction model.

XPatient Code	Trigger	Allergen	Time	Severity	Class	OPLSD A score ^a	Predicted score for T2	OPLSD A score ^b	Predicted score for T1
P17_T2	Food	Almond	T2	Moderate	T2	1	1.000	0	0.000
P9_T2	Food	Cashew	T2	Moderate	T2	1	1.000	0	0.000
P8_T2	Food	Mussel	T2	Moderate	T2	1	1.000	0	0.000
P10_T2	Food	Orange	T2	Severe	T2	1	1.000	0	0.000
P2_T2	Food	Walnut	T2	Moderate	T2	1	1.000	0	0.000
P15_T2	Food	Salad	T2	Moderate	T2	1	1.000	0	0.000
P17_T1	Food	Almond	T1	Moderate	T1	0	-0.001	1	1.001
P9_T1	Food	Cashew	T1	Moderate	T1	0	0.000	1	1.000
P8_T1	Food	Mussel	T1	Moderate	T1	0	0.000	1	1.000
P10_T1	Food	Orange	T1	Severe	T1	0	0.001	1	0.999
P2_T1	Food	Walnut	T1	Moderate	T1	0	0.000	1	1.000
P15_T1	Food	Lettuce	T1	Moderate	T1	0	0.000	1	1.000
P4_T1	Drug	Amoxicillin	T1	Severe	-	-	0.168	-	0.832
P1_T1	Drug	Carmellose	T1	Moderate	-	-	0.458	-	0.542
P7_T1	Drug	Moxifloxacin	T1	Severe	-	-	0.092	-	0.908
P16_T1	Drug	Clavulanic acid	T1	Moderate	-	-	0.812	-	0.188
P18_T1	Drug	Celecoxib	T1	Severe	-	-	0.579	-	0.421
P13_T1	Drug	Diclofenac	T1	Severe	-	-	0.607	-	0.393
P12_T1	Drug	Metamizole	T1	Severe	-	-	0.590	-	0.410
P3_T1	Drug	Iomeprol	T1	Moderate	-	-	0.728	-	0.272
P14_T1	Drug	Ampicillin	T1	Moderate	-	-	0.213	-	0.787

^a; Score used by the OPLS-DA model to be in the group of “Anaphylaxis by Food at T2”, ^b; or at “Anaphylaxis by Food at T1”; Predicted score cells in green means assigned group (score> 0.75, which means more than 75% of probability of similarity to one of the groups); Predicted score cells in yellow means uncertainty of assignment.

Table 3S. Significant metabolites identified for Food anaphylaxis between T1 and T2 time points.

X	LC-MS results							Food anaphylaxis T1 vs T2			
Nº	m/z	RT (min)	Polarity	Adduct	Error (ppm)	Biochemical class	Compound name	FC at T1	%Δ at T1	p value	p BH
1	598.4008	7.81	+	M+H	12	Phospholipids	1-(2-methoxy-docosanyl)-sn-glycero-3-phosphoserine	1.434	43.38	0.031	0.031
2	449.3407	8.35	+	M+Na	4	Fatty acid	C29:6	1.279	27.93	0.031	0.031
3	104.1072	0.54	+	M+H	0	Lipid metabolism	Choline [†]	1.482	48.22	0.031	0.031
4	663.9379	7.73	+	M+2H	14	Glycosphingolipid	Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)	1.435	43.54	0.031	0.031
5	620.4134	7.78	+	M+2H	8	Glycosphingolipid	Ganglioside GM3 (d18:0/22:0)	1.444	44.38	0.031	0.031
6	604.0746	8.37	+	M+H	8	Purine metabolism	GDP-alpha-D-mannose	1.873	87.31	0.031	0.031
7	641.9247	7.75	+	M+K	8	Purine metabolism	Guanosine 3',5'-bis(diphosphate)	1.448	44.84	0.031	0.031
8	522.3194	12.80	-	M+FA	2	Phospholipids	LysoPE(P-19:1)/LysoPE(19:0) [†]	0.654	-34.60	0.031	0.031
9	478.3284	12.80	+	M+H	2	Phospholipids	LysoPE(P-19:1)/LysoPE(19:0) [†]	0.654	-34.60	0.031	0.031
10	388.2534	4.02	+	M+H	5	Lipid metabolism	N-linoleoyl taurine	0.359	-64.10	0.031	0.031
11	752.5205	12.42	+	M+H	3	Phospholipids	PC(14:1/20:4)	0.465	-53.54	0.031	0.031
12	776.5385	8.92	-	M+FA	8	Phospholipids	PC(16:0/16:1) [†]	0.711	-28.93	0.031	0.031
13	732.5475	8.92	+	M+H	8	Phospholipids	PC(16:0/16:1) [†]	0.711	-28.93	0.031	0.031
14	730.5396	12.49	+	M+H	2	Phospholipids	PC(16:1/16:1)	0.458	-54.17	0.031	0.031
15	806.5704	12.23	+	M+H	1	Phospholipids	PC(18:1/24:0)	0.522	-47.83	0.031	0.031
16	872.7021	12.66	+	M+H	9	Phospholipids	PC(18:1/24:0)	0.854	-14.59	0.031	0.031
17	778.5364	12.44	+	M+H	2	Phospholipids	PC(20:5/16:1)	0.536	-46.40	0.031	0.031
18	828.5528	12.70	+	M+H	1	Phospholipids	PC(20:5/20:4)	0.502	-49.83	0.031	0.031

19	854.5672	12.70	+	M+H	3	Phospholipids	PC(20:5/22:5)	0.526	-47.40	0.031	0.031
20	672.5264	9.55	+	M+Na	6	Phospholipids	PC(O-14:0/O-14:0)	0.826	-17.36	0.031	0.031
21	790.5896	9.22	+	M+H	8	Phospholipids	PC(P-16:0/22:6)/PS(P-16:0/21:0)	0.867	-13.33	0.031	0.031
22	684.5614	11.04	+	M+H-H2O	11	Phospholipids	PC(P-16:0/P-16:0)	0.744	-25.65	0.031	0.031
23	716.5527	9.54	+	M+H	9	Phospholipids	PC(P-18:0/14:1)	0.799	-20.11	0.031	0.031
24	419.1667	7.97	+	M+K	6	Peptide	Phe Lys Ser	0.824	-17.60	0.031	0.031
25	890.5218	12.80	+	M+K	11	Phospholipids	PS(20:5/21:0)	0.667	-33.27	0.031	0.031
NMR results											
Nº	δ (ppm)					Biochemical class	Compound name	FC at T1	%Δ at T1	p value	p BH
26	1.89-1.91					Energy metabolism	Acetate	1.192	19.20	0.031	0.031
27	3.01-3.02					Aminoacids	Creatine	1.135	13.47	0.031	0.031
28	2.08-2.15					Aminoacids	Glutamine	1.086	8.58	0.031	0.031
29	1.86-1.89					Aminoacids	Lysine	1.154	15.39	0.031	0.031
30	7.30-7.33					Aminoacids	Phenylalanine	1.177	17.72	0.031	0.031

X

NOTE: [†] Annotation confirmed after tandem mass experiments. Those *p*-values and *p*BH (Benjamini-Hochberg correction known as False Discovery Rate: FDR) were obtained using Wilcoxon signed-rank test. RT= Retention time, FC= Fold change (calculated as T1/T2), %Δ= Percentage of change.

Table 4S
Significant metabolites identified for Moderate at e an ap hyl axi s be tw ee n T1 an

LC-MS results	Moderate T1 vs T2

d
T2
ti
me
po
int
s.
X

Nº	<i>m/z</i>	RT (min)	Polarit y	Adduct	Error (ppm)	Biochemical class	Compound name	FC at T1	%Δ at T1	<i>p</i> value	<i>p</i> BH
1	531.4041	11.99	+	M+H	1	Vitamin E compounds	alpha-Tocopherol succinate	0.821	-17.85	0.047	0.047
2	728.5870	11.02	+	M+H	11	Ceramides	CerP(d18:1/24:1)	0.842	-15.85	0.031	0.043
3	104.1072	0.54	+	M+H	3	Lipid metabolism	Choline [†]	1.461	46.09	0.031	0.042
4	1220.8362	12.63	+	M+H-H2O	10	Glycosphingolipid	Fucalpha1-2Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)	0.378	-62.23	0.031	0.043
5	537.3924	8.11	+	M+H	2	Phospholipids	LysoPA(a-25:0)	0.666	-33.45	0.031	0.043
6	547.3607	9.33	+	M+Na	0	Phospholipids	LysoPC(18:0)	0.796	-20.44	0.047	0.047
7	478.3284	12.80	+	M+H/ M+H-H2O	2	Phospholipids	LysoPE(P-19:1)/LysoPE(19:0) [†]	0.612	-38.80	0.031	0.043
8	593.4767	9.89	+	M+K	13	Fatty acid	Oleyl arachidonate	0.554	-44.58	0.031	0.043
9	800.5456	12.70	-	M+FA	1	Phospholipids	PC(16:1/18:2) [†]	0.443	-55.70	0.031	0.047
10	756.5546	12.70	+	M+H	1	Phospholipids	PC(16:1/18:2) [†]	0.443	-55.70	0.031	0.047
11	872.5384	12.71	+	M+Na	3	Phospholipids	PC(16:1/22:6) [†]	0.634	-36.61	0.031	0.043
12	872.7021	12.66	+	M+H	9	Phospholipids	PC(18:1/24:0)	0.843	-15.72	0.016	0.042
13	804.5525	12.71	+	M+H	2	Phospholipids	PC(20:4/18:3)	0.627	-37.33	0.047	0.047
14	854.5672	12.70	+	M+H	3	Phospholipids	PC(20:4/22:6)	0.558	-44.24	0.016	0.042

15	778.5364	12.44	+	M+H	2	Phospholipids	PC(20:5/16:1)	0.514	-48.59	0.031	0.043
16	828.5528	12.70	+	M+H	1	Phospholipids	PC(20:5/20:4)#	0.479	-52.14	0.047	0.042
17	890.5218	12.80	+	M+K	14	Phospholipids	PC(22:6/20:5)	0.645	-35.53	0.031	0.043
18	772.6145	10.54	+	M+H	9	Phospholipids	PC(P-18:0/18:1)	0.594	-40.63	0.047	0.047
19	766.5306	8.77	+	M+H	10	Phospholipids	PE(18:1/20:4)	0.287	-71.35	0.016	0.042
20	685.4353	12.68	+	M+K	5	Ceramides	PE-Cer(d14:2/18:0(2OH))	1.589	58.85	0.031	0.043
21	208.1329	2.88	+	M+H	1	Peptides	Phenyl-Leucine	0.800	-19.96	0.031	0.043
22	665.4384	8.95	+	M+H	12	Eicosanoids	Prostaglandin F2a-biotin	0.614	-38.60	0.031	0.043
23	722.5034	8.78	+	M+H	9	Phospholipids	PS(18:0/13:0)	0.378	-62.15	0.031	0.043
24	736.5414	12.67	+	M+H	10	Phospholipids	PS(O-16:0/17:0)	1.942	94.24	0.031	0.043

NMR results

N°	δ (ppm)	Biochemical class	Compound name	FC at T1	% Δ at T1	p value	p BH
26	1.89-1.91	Energy metabolism	Acetate	1.228	22.79	0.016	0.020
27	1.09-1.12	Fatty acid	α -Ketoisovaleric acid	1.123	12.32	0.016	0.020
28	1.61-1.65	Aminoacids	Arginine	1.104	10.45	0.016	0.020
29	2.82-2.86	Aminoacids	Asparagine	1.131	13.08	0.016	0.020
30	3.18-3.21	Phospholipids	Choline containing metabolites (choline, phosphocholine and glycerophosphocholine)	1.102	10.16	0.016	0.020
31	3.01-3.02	Aminoacids	Creatine	1.137	13.66	0.016	0.020
32	4.03-4.04	Aminoacids	Creatinine	1.069	6.94	0.016	0.020
33	2.08-2.15	Aminoacids	Glutamine	1.112	11.16	0.016	0.020
34	3.55-3.57	Sugar alcohols	Glycerol	1.175	17.50	0.016	0.020

35	3.54-3.55	Aminoacids	Glycine	1.137	13.67	0.016	0.020
36	7.03-7.05	Aminoacids	Histidine	1.139	13.90	0.016	0.020
37	0.90-0.93	Aminoacids	Isoleucine	1.130	13.02	0.016	0.020
38	0.93-0.94	Aminoacids	Isoleucine/Leucine	1.130	12.99	0.016	0.020
39	1.30-1.32	Energy metabolism	Lactate	1.326	32.62	0.016	0.020
40	0.94-0.96	Aminoacids	Leucine	1.113	11.27	0.016	0.020
41	2.71-2.78	Lipid metabolism	Lipids (-CH=CH-CH ₂ -CH=CH-)	1.108	10.81	0.047	0.047
42	1.95-2.01	Lipid metabolism	Lipids (-CH ₂ -CH = CH)	1.144	14.42	0.031	0.035
43	0.80-0.85	Lipid metabolism	Lipoprotein methyl group signal	1.115	11.49	0.016	0.020
44	1.86-1.89	Aminoacids	Lysine	1.150	15.00	0.016	0.020
45	4.04-4.06	Energy metabolism	Myo-inositol	1.128	12.83	0.031	0.035
46	2.01-2.07	Energy metabolism	NAC (N-acetyl resonances from glycans)	1.155	15.49	0.016	0.020
47	7.30-7.33	Aminoacids	Phenylalanine	1.172	17.24	0.016	0.020
48	2.32-2.35	Aminoacids	Proline	1.200	19.99	0.016	0.020
49	3.93-3.99	Aminoacids	Serine	1.103	10.27	0.016	0.020
50	7.17-7.20	Aminoacids	Tyrosine	1.158	15.85	0.016	0.020
51	1.01-1.04	Aminoacids	Valine	1.084	8.40	0.031	0.035
52	1.20-1.25	Lipid metabolism	VLDL/LDL(CH ₂) _n	1.119	11.88	0.031	0.035

NOTE: † Annotation confirmed after tandem mass experiments; & Annotation confirmed with commercial standard. Those *p*-values and *p*BH (Benjamini-Hochberg correction known as False Discovery Rate: FDR) were obtained using Wilcoxon signed-rank test. RT=

Retention time, FC= Fold change (calculated as $T1/T2$), $\% \Delta$ = Percentage of change.

Table 5S. Significant metabolites identified for Severe anaphylaxis between T1 and T2 time points.x

X	LC-MS results							Severe T1 vs T2			
Nº	<i>m/z</i>	RT (min)	Polarity	Adduct	Error (ppm)	Biochemical class	Compound name	FC at T1	%Δ at T1	<i>p</i> value	<i>p</i> BH
1	830.5698	11.57	+	M+H	0	Phospholipids	PC(20:4/20:4) [†]	1.772	77.24	0.031	0.031
2	874.5608	11.57	-	M+FA	0	Phospholipids	PC(20:4/20:4) [†]	1.772	77.24	0.031	0.031
3	634.4511	8.82	+	M+H	11	Phospholipids	PE(16:1/12:0) [†]	1.166	16.60	0.031	0.031

NOTE: [†] Annotation confirmed after tandem mass experiments. Those *p*-values and *p*BH (Benjamini-Hochberg correction known as False Discovery Rate: FDR) were obtained using Wilcoxon signed-rank test. RT= Retention time, FC= Fold change (calculated as T1/T2), %Δ= Percentage of change.

Table 6S. Significant metabolites identified for Severe vs Moderate anaphylaxis at T1 time point.X

X	LC-MS results							Severe vs Moderate at T1.			
Nº	<i>m/z</i>	RT (min)	Polarity	Adduct	Error (ppm)	Biochemical class	Compound name	FC severe	%Δ severe	<i>p</i> value	<i>p</i> BH
1	407.2094	5.8	-	M+FA-H	5	Lipid metabolism	Cortisol ^{&}	4.953	395.32	0.001	0.030
2	178.0519	3.83	-	M-H	5	Benzoic acid derivates	Hippuric acid [†]	2.497	149.75	0.049	0.049
3	311.1418	4.62	-	M-H	6	Peptides	Phe Phe [†]	2.071	107.05	0.026	0.049
NMR results											
Nº	δ (ppm)					Biochemical class	Compound name	FC severe	%Δ severe	<i>p</i> value	<i>p</i> BH
4	5.21-5.23					Energy metabolism	Glucose	1.194	19.36	0.049	0.049
5	5.24-5.36					Lipid metabolism	Lipids (-CH=CH-)	1.357	35.69	0.049	0.049
6	2.71-2.78					Lipid metabolism	Lipids (-CH=CH-CH ₂ -CH=CH-)	1.318	31.83	0.012	0.049
7	0.85-0.90					Lipid metabolism	Lipoprotein methyl group signal	1.343	34.31	0.049	0.049

NOTE: [†] Annotation confirmed after tandem mass experiments; [&] Annotation confirmed with commercial standard. Those *p*-values and *p*BH (Benjamini-Hochberg correction known as False Discovery Rate: FDR) were obtained using Mann-Whitney U test. RT= Retention time, FC= Fold change (calculated as Severe/Moderate), %Δ= Percentage of change.

Table 7S. Significant metabolites identified for Severe vs Moderate anaphylaxis at T0 time point.x

N°	LC-MS results							Severe vs Moderate at T0			
	<i>m/z</i>	RT (min)	Polarity	Adduct	Error (ppm)	Biochemical class	Compound name	FC severe	%Δ severe	<i>p</i> value	<i>p</i> BH
1	118.0862	0.55	+	M+H	0	Aminoacids	Betaine [†]	0.481	-51.90	0.045	0.045
2	407.2094	5.8	-	M+FA-H	5	Lipid metabolism	Cortisol ^{&}	0.141	-85.90	0.003	0.031
3	282.2793	9.50	+	M+H-H ₂ O	0	Lipid metabolism	Oleamide ^{&}	5.251	425.06	0.045	0.045
4	798.5294	11.92	-	M+FA	0	Phospholipids	PC(14:0/20:4)#	1.958	95.78	0.045	0.045
5	754.5384	11.92	+	M+H	0	Phospholipids	PC(14:0/20:4)#	1.958	95.78	0.045	0.045
NMR results											
N°	δ (ppm)					Biochemical class	Compound name	FC severe	%Δ severe	<i>p</i> value	<i>p</i> BH
6	1.09-1.12					Fatty acid	α-Ketoisovaleric acid	1.179	17.91	0.029	0.043
7	1.30-1.32					Energy metabolism	Lactate	1.352	35.17	0.043	0.043
8	5.24-5.36					Lipid metabolism	Lipids (-CH=CH-)	1.294	29.37	0.029	0.043
9	2.71-2.78					Lipid metabolism	Lipids (-CH=CH-CH ₂ -CH=CH-)	1.321	32.09	0.043	0.043
10	1.95-2.01					Lipid metabolism	Lipids (-CH ₂ -CH=CH)	1.196	19.60	0.043	0.043

NOTE: [†] Annotation confirmed after tandem mass experiments; [&] Annotation confirmed with commercial standard. Those *p*-values and *p*BH (Benjamini-Hochberg correction known as False Discovery Rate: FDR) were obtained using Mann-Whitney U test. RT= Retention time, FC= Fold change (calculated as Severe/Moderate), %Δ= Percentage of change.

REFERENCES

1. Pena-Bautista C, Roca M, Hervás D, Cuevas A, Lopez-Cuevas R, Vento M, et al. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. *J Proteomics*. 2019;200:144-52.
2. Kuligowski J, Sánchez-Illana Á, Sanjuán-Herráez D, Vento M, Quintás G. Intra-batch effect correction in liquid chromatography-mass spectrometry using quality control samples and support vector regression (QC-SVRC). *Analyst*. 2015;140(22):7810-7.
3. Rodríguez-Coira J, Delgado-Dolset MI, Obeso D, Dolores-Hernández M, Quintás G, Angulo S, et al. Troubleshooting in Large-Scale LC-ToF-MS Metabolomics Analysis: Solving Complex Issues in Big Cohorts. *Metabolites*. 2019;9(11).
4. Gil de la Fuente A, Godzien J, Fernández López M, Rupérez FJ, Barbas C, Otero A. Knowledge-based metabolite annotation tool: CEU Mass Mediator. *J Pharm Biomed Anal*. 2018;154:138-49.
5. Gil-de-la-Fuente A, Godzien J, Saugar S, Garcia-Carmona R, Badran H, Wishart DS, et al. CEU Mass Mediator 3.0: A Metabolite Annotation Tool. *J Proteome Res*. 2019;18(2):797-802.
6. Triba MN, Le Moyec L, Amathieu R, Goossens C, Bouchemal N, Nahon P, et al. PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. *Mol Biosyst*. 2015;11(1):13-9.
7. Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. *Curr Metabolomics*. 2016;4(2):97-103.
8. Brown M, Dunn WB, Ellis DI, Goodacre R, Handl J, Knowles JD, et al. A metabolome pipeline: from concept to data to knowledge. *Metabolomics*. 2005;1(1):39-51.